Gilead Sciences | GILD - Biaya Operasional





Biaya Operasional Perubahan Tanggal
AbbVie USD 10.27B 538M 2026-03
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
ALKERMES USD 1.75B 1.43B 2026-03
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Amgen USD 4.78B 1.12B 2026-03
Biogen USD 1.96B 69.6M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Coherus Biosciences USD 51.83M 2.48M 2025-12
Eli Lilly USD 10.02B 285M 2026-03
Gilead Sciences USD 23.52B 18.55B 2026-03
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
Glaxosmithkline GBP 5.34B 3.83B 2026-03
Incyte USD 5.62B 4.5B 2026-03
J&J USD 17.44B 1.53B 2026-03
Merck USD 18.17B 8.01B 2026-03
Moderna USD 1.78B 242M 2026-03
Neurocrine Biosciences USD 599.9M 22.3M 2026-03
Novartis USD 9.29B 507M 2026-03
Pfizer USD 90.1B 77.19B 2026-03
PTC Therapeutics USD 226.66M 19.64M 2026-03
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 9.31B 1.2B 2026-03
Sarepta Therapeutics USD 372.37M 480.65M 2026-03
United Therapeutics USD 5.9B 5.1B 2026-03
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03